Cocaine and caffeine: conditioned place preference, locomotor activity, and additivity.
J B Bedingfield, D A King, F A Holloway
https://pubmed.ncbi.nlm.nih.gov/9768563Actively Recruiting
Led by Hsiao-Ying Wey · Updated on 2025-01-09
12
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating how caffeine intake influences the learning process through reward feedback compared to a placebo. This study focuses on healthy adults aged 18 to 45 and aims to better understand the role of caffeine in dopamine-related reinforcement learning. The research explores interactions between adenosine 2A receptors and dopamine D2 receptors in the brain, which are important for learning and behavior, using advanced brain imaging techniques. Participants will take part in a double-blind randomized crossover study where they receive either a 200mg caffeine tablet or a placebo lactose tablet. Before each study day, participants undergo a 6-day period without caffeine, alcohol, or drugs and maintain regular sleep schedules. On the seventh day, they undergo simultaneous PET/fMRI brain scans after taking the assigned tablet 20 minutes prior to scanning. These scans will measure dopamine receptor availability and brain activity during reinforcement learning and motor inhibition tasks. During the study visits, participants complete a Probabilistic Selection Task (reinforcement learning) and a Go/NoGo task (motor inhibition) while being scanned. Researchers monitor dopamine D2/D3 receptor availability with PET using a radioactive dye and brain activity with fMRI. The study also assesses salience attribution after scanning. Safety is monitored, and participants' adherence to the washout period is required. The main outcomes include dopamine receptor availability and effects of caffeine on learning tasks during the scan. The total participation includes the washout and scan days, with follow-up assessments after the scan.
CONDITIONS
Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 days
Participants abstain from caffeinated dietary sources, alcohol, and drugs while maintaining regular bed and wake times.
Daily ambulatory period with no visits
Duration - 1 day
Participants receive either a caffeine or placebo tablet 20 minutes prior to a PET/fMRI scan to assess the effects on reinforcement learning and dopamine receptor availability.
1 visit (in-person PET/fMRI scan day)
Duration - 6 days
Participants abstain from caffeinated dietary sources, alcohol, and drugs while maintaining regular bed and wake times before crossing over to the other treatment condition.
Daily ambulatory period with no visits
Duration - 1 day
Participants receive the alternate treatment (caffeine or placebo) 20 minutes prior to a PET/fMRI scan to assess the effects on reinforcement learning and dopamine receptor availability.
1 visit (in-person PET/fMRI scan day)
Total: 1 location
1
Athinoula A. Martinos Center for Biomedical Imaging
Charlestown, Massachusetts, United States, 02129
Actively Recruiting
H
Hsiao-Ying Wey, PhD
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
J B Bedingfield, D A King, F A Holloway
https://pubmed.ncbi.nlm.nih.gov/9768563Erin K Moran, Adam J Culbreth, Sridhar Kandala...
https://pubmed.ncbi.nlm.nih.gov/31464449Nora D Volkow, Gene-Jack Wang, Frank Telang...
https://pubmed.ncbi.nlm.nih.gov/18716203Valtteri Kaasinen, Sargo Aalto, Kjell Någren...
https://pubmed.ncbi.nlm.nih.gov/15076753N D Volkow, G-J Wang, J Logan...
https://pubmed.ncbi.nlm.nih.gov/25871974Sergi Ferré, Jordi Bonaventura, Dardo Tomasi...
https://pubmed.ncbi.nlm.nih.gov/26051403